کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5882239 | 1149455 | 2016 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies
ترجمه فارسی عنوان
سرطان کولورکتال متاستاتیک: یک بررسی منظم از ارزش فعلی درمان
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
شیمی درمانی، سرطان روده بزرگ، هزینه بهره وری، نسبت هزینه بهره افزایشی، ارزش،
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیهوشی و پزشکی درد
چکیده انگلیسی
To evaluate, from a US payer perspective, the cost-effectiveness of treatment strategies for metastatic colorectal cancer (mCRC), we performed a systematic review of published cost-effectiveness analyses. We identified 14 papers that fulfilled our search criteria and revealed varying levels of value among current treatment strategies. Older agents such as 5-fluorouracil, irinotecan, and oxaliplatin provide high-value treatments. More modern agents targeting the EGFR or VEGF pathways, such as bevacizumab, cetuximab, and panitumumab, do not appear to be cost-effective treatments at their current costs. The analytical methods used within the papers varied widely, and this variation likely plays a significant role in the heterogeneity in incremental cost-effectiveness ratios. The cost-effectiveness of current treatment strategies for mCRC is highly variable. Drugs recently approved by the US Food and Drug Administration for mCRC are not cost-effective, and this is primarily driven by high drug costs.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Colorectal Cancer - Volume 15, Issue 1, March 2016, Pages 1-6
Journal: Clinical Colorectal Cancer - Volume 15, Issue 1, March 2016, Pages 1-6
نویسندگان
Daniel A. Goldstein, Simon B. Zeichner, Catherine M. Bartnik, Eli Neustadter, Christopher R. Flowers,